Download PDF

Other users also viewed these articles

Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes Ana Romero; Gemma Llauradó; José-Miguel González-Clemente;
Endocrinol Diabetes Nutr. 2021;68:741-50
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society] Juan Pedro-Botet; Vivencio Barrios; Víctor Sánchez-Margalet; Juan Tamargo; Francisco Arrieta; José Mª Gámez; José Antonio Gimeno-Orna; Carlos Escobar; Juan José Gómez-Doblas; Antonio Pérez;
Endocrinol Diabetes Nutr. 2023;70 Supl 1:51-62
Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study Felipe Pardo Lozano; Arantxa Rubio Marcos; Rosa Casañ Fernández; Amparo Bartual Rodrigo; Sergio Martínez-Hervás; Francisco Javier Ampudia-Blasco;
Endocrinol Diabetes Nutr. 2025;72: